AI Article Synopsis
- Inhibiting single cytokines in sepsis treatment had limited success due to their non-specificity, highlighting the need for more targeted cellular approaches.
- Previous research shows that mast cells play a role in fighting infections during early sepsis, and this study found that mast cell stabilizers can decrease serum TNF levels and improve survival rates in normal mice, but not in those without mast cells.
- The study highlights that mast cell stabilization could be a potential therapy for sepsis by reducing harmful factors like HMGB1 released from dying cells, suggesting new avenues for treating infectious diseases.
Article Abstract
Inhibiting single cytokines produced modest effects in clinical trials, in part because the cytokines were not specific for sepsis, and sepsis may require cellular strategies. Previous studies reported that mast cells (MCs) fight infections in early sepsis. In this study, we report that MC stabilizers restrain serum TNF levels and improve survival in wild-type but not in MC-deficient mice. Yet, MC depletion in knockout mice attenuates serum TNF but does not improve survival in sepsis. Serum HMGB1 was the only factor correlating with survival. MC stabilizers inhibit systemic HMGB1 levels and rescue mice from established peritonitis. MC stabilizers fail to inhibit HMGB1 secretion from macrophages, but they prevent apoptosis and caspase-3 activation in sepsis. These results suggest that MC stabilization provides therapeutic benefits in sepsis by inhibiting extracellular release of HMGB1 from apoptotic cells. Our study provides the first evidence that MCs have major immunological implications regulating cell death in sepsis and represent a pharmacological target for infectious disorders in a clinically realistic time frame.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3083453 | PMC |
| http://dx.doi.org/10.4049/jimmunol.1000273 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
User-Oriented Requirements for Artificial Intelligence-Based Clinical Decision Support Systems in Sepsis: Protocol for a Multimethod Research Project.
JMIR Res Protoc
January 2025
Institute for Health Care Management and Research, University of Duisburg-Essen, Essen, Germany.
Background: Artificial intelligence (AI)-based clinical decision support systems (CDSS) have been developed for several diseases. However, despite the potential to improve the quality of care and thereby positively impact patient-relevant outcomes, the majority of AI-based CDSS have not been adopted in standard care. Possible reasons for this include barriers in the implementation and a nonuser-oriented development approach, resulting in reduced user acceptance.
View Article and Find Full Text PDFSIV monoclonal antibody administration spanning treatment interruption in macaques delays viral rebound and selects escape variants.
Proc Natl Acad Sci U S A
February 2025
U.S. Military HIV Research Program, Center for Infectious Disease Research, Walter Reed Army Institute of Research, Silver Spring, MD 20910.
HIV-1 envelope broadly neutralizing antibodies represent a promising component of HIV-1 cure strategies. To evaluate the therapeutic efficacy of combination monoclonal antibodies (mAbs) in a rigorous nonhuman primate model, we tested different combinations of simian immunodeficiency virus (SIV) neutralizing mAbs in SIVmac251-infected rhesus macaques. Antiretroviral therapy-suppressed animals received anti-SIV mAbs targeting multiple Env epitopes spanning analytical treatment interruption (ATI) in 3 groups (n = 7 each): i) no mAb; ii) 4-mAb combination; and iii) 2-mAb combination.
View Article and Find Full Text PDFDirect economic costs related to antimicrobial resistance in bloodstream infections isolated from newborns in a perinatal hospital in Peru.
Int Health
January 2025
Universidad Cientifica del Sur, Villa el Salvador, Lima 15067, Perú.
Background: Antimicrobial resistance (AMR) has emerged as a priority for both public health and the global economy. Moreover, information on AMR is scarce, particularly in low/middle-income countries. We evaluated the direct economic cost of microorganisms and AMR.
View Article and Find Full Text PDFRe-evaluating large for gestational age: differential effects on perinatal outcomes in term and premature births.
Front Med (Lausanne)
January 2025
Division of Endocrinology and Metabolism, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan.
Objective: Pregnancies with large-for-gestational-age (LGA) fetuses are associated with increased risks of various adverse perinatal outcomes. While existing research primarily focuses on term neonates, less is known about preterm neonates. This study aims to explore the risks of adverse maternal and neonatal perinatal outcomes associated with LGA in term neonates and neonates with different degrees of prematurity, compared to appropriate-for-gestational-age (AGA) neonates.
View Article and Find Full Text PDFKnowledge, attitudes, and practices among physicians and pharmacists toward antibiotic use in sepsis.
Front Med (Lausanne)
January 2025
Linfen Central Hospital, Linfen, Shanxi, China.
Background: Sepsis management in the Intensive Care Unit (ICU) presents a significant challenge within contemporary healthcare. The primary challenge lies in ensuring the timely and appropriate utilization of antibiotics. Inappropriate antibiotic use in sepsis management can result in a multitude of adverse outcomes.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!